What third and fourth line options do you consider for patients with pleomorphic sarcoma and a good performance status who have progressed on standard anthracycline and gemcitabine/docetaxel?

If the pleomorphic sarcoma is a UPS/MFS - immunotherapy trials would be of interest. As always, any active clinical trials of newer drugs should be considered. SOC alternatives would include Pazopanib. There is also some data (and therefore a broader indication in EU) for trabectedin.